MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
March 1, 2011
David Williamson
Glaxo Gets Its Day in Court GlaxoSmithKline and Rite-Aid are taking Abbott's HIV drug pricing to the courts. mark for My Articles similar articles
The Motley Fool
July 19, 2010
Brian Orelli
Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so. mark for My Articles similar articles
The Motley Fool
April 16, 2009
Brian Orelli
2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing. mark for My Articles similar articles
The Motley Fool
February 18, 2010
Brian Orelli
Gilead Shareholders Are Whistling a Happy Tune Full data from the company's HIV quad pill show no major issues. mark for My Articles similar articles
The Motley Fool
January 6, 2010
Brian Orelli
Gilead Goes It Alone ... for Now Investors jump for joy as Gilead Sciences announces what on the surface sounds like rather inconsequential data. mark for My Articles similar articles
The Motley Fool
November 27, 2009
Brian Orelli
A Mostly Meaningless FDA Approval After an accelerated approval, the positive effects of a full approval are minimal for Johnson & Johnson's drug, Intelence. mark for My Articles similar articles
The Motley Fool
July 17, 2009
Brian Orelli
Have a Cocktail Two virus killers are better than one. The latest two to hook up are Gilead Sciences and Johnson & Johnson. mark for My Articles similar articles
The Motley Fool
April 15, 2011
Brian Orelli
Shedding the Pounds Through Divestiture Glaxo plans to sell 19 OTC products. mark for My Articles similar articles
The Motley Fool
September 20, 2011
Brian Orelli
Phase 3 + Phase 3 = Quad Approval Will Gilead Sciences' new four-drug HIV cocktail sell? mark for My Articles similar articles
The Motley Fool
May 24, 2004
Brian Gorman
Abbott Labs Stirs Up Criticism With politicians and the public riled up about Medicare, Abbott hiked the cost of an HIV drug. Smart move? mark for My Articles similar articles
The Motley Fool
September 28, 2009
Rick Aristotle Munarriz
Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered. mark for My Articles similar articles
The Motley Fool
August 16, 2006
S.J. Caplan
Abbott Labs' Latest Leaps Generating increased goodwill while potentially expanding its HIV drug market, together with marking progress in its new vascular stent business, proved to be a potent formula for lifting Abbott's shares early this week. Investors, take note. mark for My Articles similar articles
The Motley Fool
June 28, 2011
Brian Orelli
HIV Drug Partnership Gets a Boost Gilead and Johnson & Johnson hook up on a pair of new combo treatments. mark for My Articles similar articles
The Motley Fool
April 21, 2009
Brian Orelli
Reworking the Broken R&D Model When it comes to drug development, it's becoming increasingly clear that competition isn't always the best thing for the industry. Collaborations will help bring drugs to the market more cheaply. mark for My Articles similar articles
The Motley Fool
September 11, 2008
Brian Orelli
Glaxo's Not Gambling The pharmaceutical's deal for drug developer Cellzome is back-end loaded. mark for My Articles similar articles
The Motley Fool
June 29, 2010
Brian Orelli
Redeploying Capital? Investors Hope So. Selling a business unit won't help Abbott Labs diversify. mark for My Articles similar articles
The Motley Fool
July 27, 2011
Brian Orelli
Not Hypergrowth, but Good Enough Gilead posts a double-digit revenue gain. mark for My Articles similar articles
The Motley Fool
August 28, 2009
Brian Orelli
Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug. mark for My Articles similar articles
The Motley Fool
August 9, 2011
Brian Orelli
Some Potential Good News in Biotech The FDA should approve Gilead's Btripla. mark for My Articles similar articles
The Motley Fool
April 3, 2008
Brian Lawler
A Punch to Gilead's Competition A rival compound's bad data signals a better future for Gilead's lead drugs. mark for My Articles similar articles
The Motley Fool
February 24, 2011
Brian Orelli
Abbott: 1, Johnson & Johnson: 0 -- For Now Abbott Labs got a ruling overturned yesterday that would have cost the company $1.8 billion, yet investors let shares slip down 1%. mark for My Articles similar articles
The Motley Fool
January 27, 2011
Brian Orelli
Gilead's Once in a Decade Quarter Gilead's revenue falls for the first time in more than a decade. mark for My Articles similar articles
The Motley Fool
December 21, 2004
Brian Gorman
Bristol-Myers, Gilead Team Up The drugmakers' alliance will benefit both the companies and HIV patients. mark for My Articles similar articles
The Motley Fool
April 6, 2010
Brian Orelli
Kill It! Double-Teaming Malaria Malaria vaccine might not make Glaxo and Crucell rich, but the life-saving and PR benefits would be welcome. mark for My Articles similar articles
The Motley Fool
March 24, 2011
Brian Orelli
It's the Combo That Matters for Gilead The same efficacy with fewer pills is the headline, but it's the understory that makes Gilead Sciences' latest clinical trial success important for investors. mark for My Articles similar articles
The Motley Fool
January 27, 2010
Brian Orelli
Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that. mark for My Articles similar articles
The Motley Fool
October 17, 2008
Brian Orelli
Gilead Sciences Killed It The virus-killer kills analysts' expectations, as well. The company blows through analysts' expectations with its third-quarter results. mark for My Articles similar articles
The Motley Fool
October 28, 2004
Bill Mann
Glaxo's Mild Depression The British drug maker sees increased generic competition for its anti-depressant drugs. Total constant currency sales slipped to $7.7 billion in the current quarter from $8.5 billion last year. mark for My Articles similar articles
The Motley Fool
June 30, 2009
Brian Orelli
A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention. mark for My Articles similar articles
The Motley Fool
June 30, 2009
Brian Orelli
Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward. mark for My Articles similar articles
The Motley Fool
December 17, 2008
Brian Orelli
A Super-Cheap Call Option GlaxoSmithKline announces it's partnering up with tiny Dynavax Technologies to develop up to four drugs for autoimmune and inflammatory diseases. The pay-if-the-drug-works scheme should pay off. mark for My Articles similar articles
The Motley Fool
August 10, 2010
Brian Orelli
When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow. mark for My Articles similar articles
The Motley Fool
May 21, 2010
Brian Orelli
Abbott Learns to Say "Low Margin" in Hindi No matter what country, overpaying isn't a good idea. mark for My Articles similar articles
The Motley Fool
November 13, 2009
Brian Orelli
Abbott: Brave or Stupid? Abbott Labs announces the acquisition of PanGenetics' pain drug PG110, which is still in phase 1 trials. mark for My Articles similar articles
The Motley Fool
December 18, 2009
Brian Orelli
2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond. mark for My Articles similar articles
The Motley Fool
October 21, 2010
Brian Orelli
Abbott Just Can't Get Any Love Despite meeting or beating analysts' earnings for a streak that stretches balk half a decade, Abbott Labs hasn't been able to get much love from investors. mark for My Articles similar articles
The Motley Fool
July 29, 2010
Brian Orelli
Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company. mark for My Articles similar articles
The Motley Fool
October 20, 2011
Brian Orelli
Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other. mark for My Articles similar articles
The Motley Fool
August 4, 2010
Matt Koppenheffer
How Much Is Abbott Labs Worth? Is Abbott Labs' stock on sale? mark for My Articles similar articles
The Motley Fool
January 21, 2010
Brian Orelli
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? mark for My Articles similar articles
The Motley Fool
January 22, 2009
Brian Orelli
Abbott Labs Thumbs Nose at Recession On a GAAP basis, Abbott Labs fourth-quarter earnings per share were up a whopping 27%, and even better, the double-digit increases don't look like they're going to stop anytime soon. mark for My Articles similar articles
The Motley Fool
April 18, 2008
Brian Orelli
Big Deal for Small RNAs Glaxo buys into Regulus' microRNA research. mark for My Articles similar articles
The Motley Fool
January 27, 2011
Brian Orelli
Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out. mark for My Articles similar articles
The Motley Fool
May 24, 2011
Brian Orelli
J&J Approved, but Needs Help From a Friend The HIV combo product is the key. mark for My Articles similar articles
The Motley Fool
December 31, 2007
Brian Lawler
Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year. mark for My Articles similar articles
The Motley Fool
July 17, 2008
Brian Orelli
Investors Yawn at Abbott Labs' Growth Abbott Labs may be firing on all cylinders, but investors were less than impressed with its earnings release mark for My Articles similar articles
The Motley Fool
April 23, 2009
Brian Orelli
Hitting the Patent Cliff Early Glaxo is at the front edge of a patent cliff. But that means that when other drugmakers are hurting a few years down the road, Glaxo should be sitting pretty, seeing the fruits of all those partnerships it's investing in now. mark for My Articles similar articles
The Motley Fool
February 8, 2008
Brian Lawler
Hold on to GlaxoSmithKline This might be a tough year for the big pharma company, but its pipeline makes it a keeper. mark for My Articles similar articles
The Motley Fool
June 15, 2004
Brian Gorman
Abbott's Gambit Abbott Laboratories is making a high-stakes stand on drug pricing in a dispute that threatens to make hostages out of the pharmaceutical industry and its investors. mark for My Articles similar articles
The Motley Fool
February 26, 2010
Brian Orelli
Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue. mark for My Articles similar articles